Eli Lilly (NYSE: LLY) confirmed via its Canadian unit on Monday that its flagship Alzheimer’s therapy Kisunla (donanemab) has secured regulatory clearance from Health Canada for use in patients with early symptomatic Alzheimer’s disease.
The approval expands Kisunla’s global footprint to 48 international markets, and positions it as Canada’s first and only amyloid plaque-targeting therapy backed by clinical evidence allowing treatment discontinuation following successful amyloid clearance. The milestone reshapes the competitive and clinical landscape for early Alzheimer’s intervention across the country.
Per Lilly’s official filing, Kisunla is approved for adult patients diagnosed with Alzheimer’s-related mild cognitive impairment (MCI) or mild dementia. Eligible candidates are limited to ApoE ε4 heterozygotes or non-carriers with confirmed amyloid pathology. The therapy is administered on a once-monthly dosing regimen, functioning to clear accumulated amyloid plaques in the brain — a key pathological driver of the cognitive impairment and memory loss associated with Alzheimer’s.
Clinical outcomes from the pivotal Phase 3 TRAILBLAZER-ALZ 2 trial form the foundation of the approval. The trial demonstrated Kisunla cuts patients’ risk of advancing to a more severe disease stage by 40%. Early-stage MCI patients registered the strongest clinical benefit, with a 35% deceleration in cognitive and functional decline over an 18-month period, while the overall study population recorded a 22% slowdown in disease deterioration. A standout clinical feature is its flexible treatment course: eligible patients may discontinue therapy as early as six months post plaque clearance, with nearly half able to end treatment within 12 months.
Canada faces mounting public health pressure from Alzheimer’s prevalence. As of 2025, over 770,000 Canadians live with the disease, with prevalence projected to double by 2050. Ranked among the nation’s top causes of mortality and disability, Alzheimer’s imposes an estimated annual economic burden of CAD 40 billion. The latest regulatory green light fills a long-unmet clinical gap in early targeted treatment, while further solidifying Lilly’s leadership in the global neuroscience pipeline.
Notwithstanding its landmark approval, Kisunla continues to stir industry debate over tangible clinical value. In April 2025, a comprehensive review published by the Cochrane Collaboration noted that while donanemab achieves measurable amyloid clearance, such biological improvement may not deliver clinically meaningful patient outcomes. Trial metrics show 29% of placebo recipients experienced no disease progression, versus 47% among Kisunla-treated patients, underscoring pronounced variability in treatment response. Analysts also flag limited ethnic diversity in trial cohorts, raising questions over broader real-world applicability.
On the safety front, Kisunla is contraindicated for ApoE ε4 homozygote carriers, who face elevated risk of amyloid-related imaging abnormalities (ARIA). The class-wide side effect may trigger transient cerebral swelling and micro-bleeding, with rare instances of severe, life-threatening neurological events.
Lilly framed the Canadian approval as a landmark payoff from its 35-year commitment to Alzheimer’s R&D. The firm pledged to collaborate with Canadian health authorities and healthcare systems to expand patient access, while advancing a slate of ongoing clinical trials to further explore the therapy’s broader utility.
Industry observers contend Kisunla represents a meaningful new treatment option for early Alzheimer’s patients, yet its market uptake will hinge on insurance coverage policies, real-world efficacy validation, and sustained safety oversight.
